Fundraising Fox
/Companies
Sign in

GABA Therapeutics

Newport Beach, US · Founded 2019 · Delaware corporation · 1 known investors

Find your way into GABA Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

159 people can intro you to Kathryn

Ask Patrick Enright to introduce you to Kathryn King

You →Patrick · together at Aptinyx Inc. →Kathryn

Sign up to find every way you can get introduced to GABA Therapeutics

  • Your email: who you already know at GABA Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the GABA Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Gabar (Gabarx) is a biopharmaceutical company developing small-molecule drug candidates for central nervous system disorders such as anxiety and depression, drawing on deuterium-modified molecule chemistry. Its work spans clinical development, regulatory strategy, and CMC/quality across multiple therapeutic indications.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

DS
Dr. SaltarelliExecutive (CNS drug development)
RT
Roger TungExecutive
KKKathryn King
Kathryn KingClinical Development ExecutiveKathryn King is a clinical development executive with experience in large global pharmaceutical companies and small biotech organizations. Her expertise spans clinical operations, regulatory strategy, statistical analysis planning, data management, and quality across multiple therapeutic areas including CNS/neuroscience, infectious disease, rare disease, immunology, and oncology.
IJ
Ian John MasseyNamed on SEC filing
RG
Richard Gregory FarrellCFO
FB
Florian BrandNamed on SEC filing
ML
Matthias LuzNamed on SEC filing
CF
Christian FibigerNamed on SEC filing
OD
Olivier DasseNamed on SEC filing
DG
David George PutmanNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$22M disclosed across 2 rounds · 2019–2023

▶$500KraisedOct 2023 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan BarrettDirector
  • H. Christian FibigerDirector
  • Srinivas RaoDirector
  • Mario SaltarelliExecutive Officer, Director
  • Richard FarrellExecutive Officer, Director
Offering amount
$1M
Amount sold
$500K
First sale
Sep 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.5MraisedOct 2019 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Ian John MasseyExecutive Officer, Director
  • Richard Gregory FarrellExecutive Officer, Director
  • Florian BrandDirector
  • Matthias LuzDirector
  • Christian FibigerDirector
  • Olivier DasseExecutive Officer
  • David George PutmanExecutive Officer
Amount sold
$21.5M
Proceeds to insiders
$873.8K
First sale
Aug 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does GABA Therapeutics do?
Gabar (Gabarx) is a biopharmaceutical company developing small-molecule drug candidates for central nervous system disorders such as anxiety and depression, drawing on deuterium-modified molecule chemistry. Its work spans clinical development, regulatory strategy, and CMC/quality across multiple therapeutic indications.
Who are GABA Therapeutics's investors?
GABA Therapeutics's investors include Robin Hood Ventures.
How much funding has GABA Therapeutics raised?
GABA Therapeutics has disclosed $22M raised across 2 rounds.
Where is GABA Therapeutics headquartered?
GABA Therapeutics is headquartered in Newport Beach, US.